
HER2-Positive Gastrointestinal Cancers — Microlearning Activity 1: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
Oncology Today with Dr Neil Love
00:00
Choosing between HER2 and FGFR targeting
Haley Ellis and Lionel discuss concurrent HER2 and FGFR2 alterations and favor FGFR inhibitors as primary driver.
Play episode from 08:52
Transcript


